bioMérieux BIM.PA
bioMérieux is a French in-vitro diagnostics company that develops and markets systems, reagents, and software for medical diagnostics and industrial control, with a business model based on continuous innovation and a broad product portfolio. bioMérieux presents solid financial health with net cash (ND/EBITDA of -0.22) and an operating margin of 15.23%, although revenue growth is negative (-3.90%) and momentum is very weak (0.54).
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
bioMérieux is a French in-vitro diagnostics company that develops and markets systems, reagents, and software for medical diagnostics and industrial control, with a business model based on continuous innovation and a broad product portfolio. bioMérieux presents solid financial health with net cash (ND/EBITDA of -0.22) and an operating margin of 15.23%, although revenue growth is negative (-3.90%) and momentum is very weak (0.54).
Score by category
| Category | Score |
|---|---|
| Financial health | 7.8 |
| Quality / Moat | 6.4 |
| Valuation | 6.4 |
| Growth | 5.9 |
| Dividend | 5.3 |
| Momentum | 0.5 |
| Risk & Context | 6.9 |
OVERALL SCORE: 6.1/10
Context and risks
Elevated governance risk in France due to potential state interventionism and regulatory protectionism, although the company has a diversified global business model.
News considered in the analysis
- BioMerieux SA (BMXMF) (Q2 2026) Earnings Call Highlights: Strong Cash Flow and Strategic ... — Resultados del segundo trimestre con fuerte generación de caja, refuerza la confianza en la ejecución operativa.
- BioMerieux SA (BMXMF) Full Year 2025 Earnings Call Highlights: Strong Organic Growth and ... — Resultados anuales de 2025 ya conocidos y ampliamente cubiertos; la información está descontada en el precio.
- Why The Narrative Around bioMérieux (ENXTPA:BIM) Is Shifting As Analysts Rebalance Risk And Growth — Artículo de análisis que sugiere un cambio en la percepción de riesgo/crecimiento; impacto moderado y parcialmente descontado.
Verdict: Hold; business quality and balance sheet are solid, but lack of growth and poor momentum suggest waiting for an improvement in fundamentals before buying.
Main risk: The main risk is the slowdown in revenue growth (-3.90%), which could indicate loss of market share or a more difficult competitive environment in in-vitro diagnostics.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →